



**PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE  
BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION  
OF MAJOR SHAREHOLDINGS (THE “TRANSPARENCY LAW”)**

**GHENT, Belgium, 30 April 2010 - Ablynx NV [Euronext Brussels: ABLX]** announced today that an additional 11,624 shares have been issued by the Company in exchange for €25,391 as a result of the exercise of warrants by some employees and consultants of the Company.

As a result of such capital increase, Ablynx now has 43,601,797 shares outstanding and publishes the following information in accordance with Article 15 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"):

Total amount of the capital of the Company :	€81,486,264.59
Total number of voting securities:	43,601,797
Total number of voting rights (denominator):	43,601,797

Ablynx NV has an aggregate of 3,568,076 outstanding warrants, 2,506,512 warrants of which entitle their holders to an aggregate of 1,253,256 shares (two warrants giving right to subscribe for one share) and 1,061,564 warrants of which entitle their holders to an aggregate of 1,061,564 shares (one warrant giving right to subscribe for one share). The aggregate number of voting rights that can be obtained upon exercise of the outstanding warrants amounts to 2,314,820.

Ablynx has not issued any other rights to subscribe for voting securities that have not yet been issued or any shares without voting rights.

The voting securities of Ablynx are not divided into categories.

The Articles of Association of Ablynx provide for an additional notification threshold of 3%.

This information is valid as per 21 April 2010. In accordance with the Transparency Law, changes to the information set out above will be published ultimately by the end of the calendar month during which the relevant change has occurred.

- ends-

**About Ablynx [Euronext Brussels: ABLX] - <http://www.ablynx.com>**

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 230 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007 and raised €50 million through an SPO in March 2010.

Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. Ablynx now has over 25 programmes in its therapeutic pipeline including four Nanobodies in clinical development. So far, Nanobodies have been successfully generated against more than 190 different protein targets including several complex targets such as chemokines, GPCRs, ion channels and viruses, which are typically very difficult to approach with conventional monoclonal antibodies. Efficacy data have been obtained in 28 *in vivo* models for Nanobodies against a range of different targets.

Ablynx has an extensive patent position in the field of Nanobodies for healthcare applications. It has exclusive and worldwide rights to more than 130 families of granted patents and pending patent applications, including the Hamers patents covering the basic structure, composition, preparation and uses of Nanobodies.

Ablynx has ongoing research collaborations and significant partnerships with several major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Pfizer (previously Wyeth Pharmaceuticals). Ablynx is building a diverse and broad portfolio of therapeutic Nanobodies through these collaborations as well as through its own internal discovery programmes.

The Company's lead programme, ALX-0081, an intravenously administered novel anti-thrombotic entered a Phase II study in patients undergoing percutaneous coronary intervention (PCI) in September 2009. Ablynx demonstrated proof-of-concept by biomarker for ALX-0081 in December 2009. ALX-0681, a subcutaneous administration of the anti-von Willebrand factor (vWF) Nanobody has concluded Phase I. In September 2009, Ablynx's partner Pfizer entered a Phase II study in RA patients, with an anti-TNF-alpha Nanobody.

In December 2009, Ablynx initiated a double-blind, randomised, placebo-controlled Phase I study with ALX-0141, a Nanobody targeting Receptor Activator of Nuclear Factor kappa B Ligand (RANKL), in healthy postmenopausal women. ALX-0061, an anti-IL6R Nanobody is in preclinical development for the treatment of autoimmune and inflammatory diseases. More recently, in February 2010, Ablynx announced that it reached its criteria for preclinical development for ALX-0651, a Nanobody against CXCR4, and Ablynx will progress this programme towards the clinic. CXCR4 plays an important role in cell movement, tumor growth and metastasis.

In March 2010, Ablynx advanced ALX-0171, an anti-RSV Nanobody, into pre-clinical development for the treatment of respiratory syncytial virus (RSV) infections. ALX-0171 binds to RSV and neutralizes the virus. The Nanobody will be administered via the lungs and based on the *in vivo* data it has the potential to be effective both in the prevention of infection as well as in treatment once infection has occurred.

Nanobody<sup>®</sup> is a registered trademark of Ablynx NV.

**For more information, please contact Ablynx:**

Dr Edwin Moses  
Chairman and CEO  
t: +32 (0)9 262 00 07  
m: +44 (0)7771 954 193 /  
+32 (0)473 39 50 68  
e: [edwin.moses@ablynx.com](mailto:edwin.moses@ablynx.com)

Eva-Lotta Allan  
Chief Business Officer  
t: +32 (0)9 262 00 75  
m: +32 (0)475 78 36 21 /  
+44 (0)7990 570 900  
e: [eva-lotta.allan@ablynx.com](mailto:eva-lotta.allan@ablynx.com)

Wim Ottevaere  
Chief Financial Officer  
t: +32 (0)9 262 00 08  
e: [wim.ottevaere@ablynx.com](mailto:wim.ottevaere@ablynx.com)

*Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events*

*described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.*